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February 2016 Abstracts S31sequenced the miRNA in these cells and found that cells
with EMT memory have distinct miRNA proﬁle
compared to cells with transient EMT, suggesting that
the epigenetic switch upon chronic IL-1b exposure leads
to selective gene expression. These ﬁndings, for the ﬁrst
time, demonstrate a unique feature in chronic inﬂam-
mation that allows cells to metastasize and eventually
grow in distant organs, suggesting that these cells may
serve as a reservoir for tumor metastasis and relapse.
The intent of this study is to ultimately identify targets to
intervene in preventing and treating metastatic behavior
in lung cancer.
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Background: The randomized, double-blind, placebo-
Controlled Study of Lanreotide Antiproliferative
Response in Neuroendocrine Tumors (CLARINET)
showed that treatment with the somatostatin analog
(SSA) lanreotide depot was associated with signiﬁcantly
prolonged progression-free survival (PFS) vs placebo
(PBO) in gastroenteropancreatic neuroendocrine tumors
(GEP-NETs), leading to FDA approval. Like GEP-NETs,
lung NETs express somatostatin receptors.
Methods: This multi-institutional study will enroll an
anticipated216patientswith lowgrademetastatic and/or
un-resectable NETs that have positive somatostatin scin-
tigraphy and who are treatment naïve or have had no
more than 1 course of systemic chemotherapy (cytotoxic,
molecular targeted therapy or interferon). Patients will be
randomized 2:1 to receive lanreotide depot 120 mg via
deep subcutaneous injection plus best standard of care or
PBO. An estimated 175PFS events (disease progression or
death) on both arms will provide a 90% power to detect a
statistically signiﬁcant treatment effect using a two-sided
log rank test at a signiﬁcance level of a¼0.05.
Results: Anticipated results include the primary
endpoint of PFS in both arms, as well as secondaryendpoints which include objective radiologic response
rate, overall survival, effects on plasma chromogranin A,
and safety/tolerability.
Conclusion: Therapeutic agents for the treatment of
lung NETs are currently limited. This study will provide
data on the efﬁcacy of lanreotide depot for patients with
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Introduction: The expression of programmed cell death
ligand 1 (PD-L1) provides limited predictive value in
identifying patients most likely to respond to immuno-
therapy. Since the heterogeneity of PD-L1 expression
may lead to sampling error and the misclassiﬁcation of
PD-L1 status, we assessed the heterogeneity of PD-L1
expression in paired resected multifocal lung cancers
with the hypothesis that expression is heterogeneous.
Methods: PD-L1 was assessed by immunohistochem-
istry (CellSignaling #13684 clone E1L3N). Five percent
or greater membranous expression was considered
positive. A chromosomal rearrangement-based next-
generation sequencing approach was used to deﬁne
paired lesions as independent primaries or related le-
sions. Descriptive and agreement statistics were used for
analysis.
Results: A total of 67 multifocal lung cancers from 32
patients were sequenced and stained for PD-L1. There
was agreement of PD-L1 expression by the tumor cells in
paired lesions of 20 patients, and disagreement of PD-L1
expression by the tumor cells in paired lesions of 12
patients (kappa¼0.01). Sequencing identiﬁed that 23
patients had independent primary lung cancers and that
nine patients had related cancers. Amongst the patients
with independent cancers, there was agreement of
PD-L1 expression by the tumor cells in paired lesions of
12 patients, and disagreement of PD-L1 expression by
the tumor cells in paired lesions of 11 patients
(kappa¼0.31). Amongst the patients with related lung
cancers, there was agreement of PD-L1 expression by the
tumor cells in paired lesions of 8 patients, and
disagreement of PD-L1 expression by the tumor cells in
paired lesions of 1 patient (kappa¼0.73).
Conclusion: Overall, the expression of PD-L1 is hetero-
geneous amongst paired multifocal lung cancers, but
